Valuation: Lineage Cell Therapeutics, Inc.

Market Cap 32Cr 28Cr 26Cr 24Cr 45Cr 3.02TCr 46Cr 310.4Cr 119.83Cr 1.49TCr 119.84Cr 117.21Cr 5.17TCr P/E 2026 *
-18.3x
P/E 2027 * -14x
Enterprise Value 32Cr 28Cr 26Cr 24Cr 45Cr 3.02TCr 46Cr 310.4Cr 119.83Cr 1.49TCr 119.84Cr 117.21Cr 5.17TCr EV / Sales 2026 *
17.8x
EV / Sales 2027 * 17.6x
Free-Float
95.07%
Yield 2026 *
-
Yield 2027 * -
1 day+5.47%
1 week+7.14%
Current month+1.50%
1 month+1.50%
3 months-8.16%
6 months-17.18%
Current year-19.16%
1 week 1.2
Extreme 1.2
1.36
1 month 1.18
Extreme 1.18
1.36
Current year 1.18
Extreme 1.18
1.98
1 year 0.85
Extreme 0.85
2.09
3 years 0.37
Extreme 0.3651
2.09
5 years 0.37
Extreme 0.3651
2.99
10 years 0.37
Extreme 0.3651
4
Manager TitleAgeSince
Chief Executive Officer 54 17/09/2018
Director of Finance/CFO 50 14/11/2022
Chief Operating Officer - 01/12/2010
Director TitleAgeSince
Director/Board Member 60 01/07/2009
Director/Board Member 68 11/04/2014
Chairman 60 27/04/2024
Date Insider Type Main position Quantity % Market Cap.
12/03Buy

Chief Executive Officer

15,000 0.0065%
05/03Free

Chief Financial Officer

10,50,000 0.4559%
05/03Free

Chief Executive Officer

32,50,000 1.4110%
Change 5-day change 1-year change 3-year change Capi.($)
+5.47%+7.14%+48.78%-3.57% 32Cr
+0.94%+8.20%-4.77%+1.97% 4.62TCr
+5.79%+16.17%+423.57%+634.63% 3.87TCr
+1.12%+15.18%+22.65%-12.71% 3.19TCr
+3.61%+6.69%+19.80%+62.38% 3.11TCr
+8.02%+5.23%+17.67%+35.36% 2.38TCr
+1.13%+15.66% - - 1.62TCr
+1.45%+17.35%+70.37%+127.60% 1.51TCr
-1.13%+9.05%+12.03%+18.95% 1.37TCr
-0.60%+6.32%+104.23%+96.28% 1.34TCr
Average +2.56%+10.12%+79.37%+106.76% 2.3TCr
Weighted average by Cap. +2.64%+10.07%+96.03%+142.39%

Financials

2026 *2027 *
Net sales 1.79Cr 1.57Cr 1.45Cr 1.35Cr 2.55Cr 169.59Cr 2.61Cr 17Cr 6.74Cr 84Cr 6.74Cr 6.59Cr 290.47Cr 1.81Cr 1.58Cr 1.46Cr 1.37Cr 2.57Cr 171.06Cr 2.63Cr 18Cr 6.79Cr 84Cr 6.79Cr 6.65Cr 292.99Cr
Net income -2.38Cr -2.08Cr -1.92Cr -1.8Cr -3.38Cr -224.9Cr -3.46Cr -23Cr -8.93Cr -110.95Cr -8.93Cr -8.74Cr -385.22Cr -3.17Cr -2.77Cr -2.56Cr -2.39Cr -4.5Cr -299.33Cr -4.6Cr -31Cr -12Cr -147.67Cr -12Cr -12Cr -512.69Cr
Net Debt - -
Logo Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).
Employees
75
Date Price Change Volume
30/26/30 $1.350 +5.47% 14,54,537
26/26/26 $1.280 +4.92% 2,25,39,712
25/26/25 $1.220 -3.17% 11,59,013
24/26/24 $1.260 +0.80% 7,78,140
23/26/23 $1.250 -0.79% 7,27,880
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.280USD
Average target price
5.500USD
Spread / Average Target
+329.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LCTX Stock